Flexion Therapeutics Stock News

Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $30.00. The company's shares closed

Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN – Research Report) today and set a price

Flexion Therapeutics Inc (NASDAQ:FLXN) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 8,200,000 shares, a growth of 15.5% from the

Analysts predict that Flexion Therapeutics Inc (NASDAQ:FLXN) will announce $20.60 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Flexion Therapeutics’

Investment analysts at Northland Securities began coverage on shares of Flexion Therapeutics (NASDAQ:FLXN) in a research note issued to investors on Monday, TipRanks reports. The brokerage set a “bu

ERBA Diagnostics (OTCMKTS:ERBA) and Flexion Therapeutics (NASDAQ:FLXN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their inst

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Flexion Therapeutics (FLXN) and Dexcom (DXCM) with bullish

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Flexion Therapeutics ( FLXN – Research Report ) and Dexcom ( DXCM – Research Report ) with bullish

Northland Securities analyst Carl Byrnes initiated coverage with a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $35.00. The

Northland Securities analyst Carl Byrnes initiated coverage with a Buy rating on Flexion Therapeutics (FLXN – Research Report) today and

Flexion Therapeutics, Inc. (FLXN) today announced new positive preclinical efficacy and pharmacokinetic (PK) data for FX301, its locally administered peripheral nerve block candidate for control of po

Russo Partners' Sports-Health Alliance, part of the New York City-based healthcare and technology communications firm, has launched "Stay Safe. Stay Together. Stay Healthy," a social media campaign to

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Nabriva (NBRV), with a price target of $2.50. The company's